A Multicentre, Interventional, Post-marketing, Randomised, Double-blind, Crossover Study to Evaluate the Clinical Safety and Efficacy of AbobotulinumtoxinA (Dysport) in Comparison With OnabotulinumtoxinA (Botox) When Treating Adults With Upper Limb Spasticity
Latest Information Update: 05 Feb 2025
At a glance
- Drugs Botulinum-Toxin-A (Primary)
- Indications Muscle spasticity
- Focus Adverse reactions
- Acronyms DIRECTION
- Sponsors Ipsen
Most Recent Events
- 03 Feb 2025 Planned End Date changed from 31 Mar 2026 to 31 Oct 2025.
- 03 Feb 2025 Planned primary completion date changed from 31 Mar 2026 to 31 Oct 2025.
- 28 Nov 2024 Planned number of patients changed from 450 to 465.